Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Background: Both obesity and type 2 diabetes are associated with increased morbidity and mortality. Published data suggest that orlistat 120 mg, a lipase inhibitor used to treat obesity, may improve glycaemic parameters through weight loss–independent effects. Aim: To investigate the effect of orlistat 120 mg on weight loss, and assess whether changes in glycaemic parameters [fasting plasma glucose (FPG) and haemoglobin A 1c (HbA 1c )] are independent of weight loss. Methods: This retrospective analysis of pooled data from seven multicentre, double‐blind, placebo‐controlled studies involved overweight or obese patients with type 2 diabetes (aged 18–70 years). Patients were required to have a body mass index of 27–43 kg/m 2 , HbA 1c of 6.5 to <13%, and stable weight for ≥3 months. Subjects received orlistat 120 mg tid or placebo for 6 or 12 months. Results: A total of 2550 overweight or obese patients with type 2 diabetes were enrolled and randomized to treatment with orlistat 120 mg tid (n = 1279) or placebo (n = 1271). For the whole population, patients treated with orlistat 120 mg had significantly greater mean decreases in FPG compared with placebo‐treated patients (−1.39 mmol/l vs. −0.47 mmol/l; p < 0.0001). In addition, orlistat 120 mg provided significantly larger mean decreases in HbA 1c compared with placebo (−0.74% vs. −0.31%; p < 0.0001). For patients with minimal weight loss (≤1% of baseline body weight), orlistat 120 mg still provided a significantly greater decrease in the least squares mean value for both FPG (−0.83 mmol/l vs. ±0.02 mmol/l; p = 0.0052) and HbA 1c −0.29% vs. ±0.14%; p = 0.0008). This suggested that the improvement of glycaemic control with orlistat 120 mg was independent of weight loss. Using linear regression analysis, improvement in glycaemic control (FPG and HbA 1c ) with orlistat 120 mg was less strongly correlated with weight loss than for placebo. Conclusion: Orlistat 120 mg appears to improve glycaemic control more than would be predicted by weight loss alone in overweight or obese patients with type 2 diabetes. Postulated mechanisms underlying this effect include an improvement of insulin sensitivity, a slower and incomplete digestion of dietary fat, reduction of postprandial plasma non‐esterified fatty acids, decreased visceral adipose tissue, and stimulation of glucagon‐like peptide‐1 secretion in the lower small intestine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Weight gain as a risk factor for clinical diabetes mellitus in women
Colditz, G. A., Willett, W. C., Rotnitzky, A., & Manson, J. E. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-7-199504010-00001 · Cited by 2,064
Obesity, Fat Distribution, and Weight Gain as Risk Factors for Clinical Diabetes in Men
Chan, J. M., Rimm, E. B., Colditz, G. A., Stampfer, M. J., & Willett, W. C. (1994) · Diabetes Care · doi:10.2337/diacare.17.9.961 · Cited by 1,808
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Standards of Medical Care in Diabetes—2007
American Diabetes Association (2007) · Diabetes Care · doi:10.2337/dc07-s004 · Cited by 1,190
Hollander, P. A., Elbein, S. C., Hirsch, I. B., Kelley, D., McGill, J., Taylor, T., Weiss, S. R., Crockett, S. E., Kaplan, R. A., Comstock, J., et al. (1998) · Diabetes Care · doi:10.2337/diacare.21.8.1288 · Cited by 654
Self-citationGlucagon‐like peptide‐1 cells in the gastrointestinal tract and pancreas of rat, pig and man
EISSELE, R., GÖKE, R., WILLEMER, S., HARTHUS, H. ‐., VERMEER, H., ARNOLD, R., & GÖKE, B. (1992) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1992.tb01464.x · Cited by 654
Long-term Effects of Modest Weight Loss in Type II Diabetic Patients
Wing, R. R. (1987) · Archives of Internal Medicine · doi:10.1001/archinte.1987.00370100063012 · Cited by 484
Santomauro, A. T., Boden, G., Silva, M. E., Rocha, D. M., Santos, R. F., Ursich, M. J., Strassmann, P. G., & Wajchenberg, B. L. (1999) · Diabetes · doi:10.2337/diabetes.48.9.1836 · Cited by 431
Effects of fat on glucose uptake and utilization in patients with non-insulin-dependent diabetes.
Boden, G., & Chen, X. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118160 · Cited by 344
Obesity, weight loss and prognosis in type 2 diabetes
Lean, M. E. J., Powrie, J. K., Anderson, A. S., & Garthwaite, P. H. (1990) · Diabetic Medicine · doi:10.1111/j.1464-5491.1990.tb01375.x · Cited by 318
Research works printed but not linked: 40
- 10.1001/jama.282.16.1523 · DOI · Paper page
- 10.1136/bmj.324.7331.192c · doi:10.1136/bmj.324.7331.192c
- 10.2337/diacare.23.10.1499 · DOI · Paper page
- 10.1210/rp.59.1.207 · DOI · Paper page
- 10.1007/s001250051172 · DOI · Paper page
- 10.1038/oby.2000.7 · DOI · Paper page
- 10.1016/S0140-6736(98)07019-6 · DOI · Paper page
- 10.7326/0003-4819-128-3-199802010-00001 · DOI · Paper page
- 10.2337/diacare.22.1.33 · DOI · Paper page
- 10.1001/jama.298.2.194 · DOI · Paper page
- 10.1007/s11883-008-0009-z · DOI
- Guerciolini R, 1997, Mode of action of orlistat, Int J Obes, 21, S12
- 10.1046/j.1365-2796.2000.00720.x · DOI · Paper page
- 10.2337/diacare.27.1.33 · DOI · Paper page
- Expert Committee of the Canadian Diabetes Advisory Board, 1992, Clinical practice guidelines for treatment of diabetes mellitus, Can Med Assoc J, 147, 697
- 10.1016/S0149-2918(96)80057-9 · DOI · Paper page
- 10.1111/j.1464-5491.2004.01474.x · DOI · Paper page
- Jacob S, 2006, Orlistat has positive effects on glycaemic control in type 2 diabetes beyond the improvements produced by weight loss alone, Obes Rev, 7
- 10.4158/EP.7.1.44 · DOI
- Carpentier A, 1999, Acute enhancement of insulin secretion by FFA in humans is lost with prolonged FFA elevation, Am J Physiol, 276, E1055
- 10.2337/diabetes.49.3.399 · DOI · Paper page
- 10.2337/diab.42.11.1567 · DOI · Paper page
- 10.1046/j.1464-5491.2002.00823.x · DOI · Paper page
- Björntorp P, 1996, The regulation of adipose tissue distribution in humans, Int J Obes, 20, 291
- 10.1016/0026-0495(92)90016-4 · DOI · Paper page
- 10.1093/ajcn/79.1.22 · DOI
- Mendoza‐Guadarrama LG, 2000, Orlistat reduces visceral fat independent of weight changes in obese diabetics type 2, Int J Obes, 24
- 10.1046/j.1463-1326.2003.00262.x · DOI · Paper page
- 10.1111/j.1464-5491.2005.01723.x · DOI · Paper page
- 10.1093/ije/dyi253 · DOI · Paper page
- 10.1007/BF02064202 · DOI · Paper page
- 10.1152/ajpgi.00411.2005 · DOI
- 10.2337/diacare.27.5.1077 · DOI
- 10.1210/jc.2003-030199 · DOI · Paper page
- 10.1152/ajpgi.00512.2002 · DOI · Paper page
- 10.1016/S0016-5085(98)70640-7 · DOI
- 10.1136/gut.46.6.774 · DOI
- Serrano‐Rios M, 2001, Orlistat efficacy on weight loss in overweight or obese patients with type 2 diabetes mellitus. Spanish randomized clinical trial [abstract], Diabetes, 50
- Bonnici F, 2002, Effect of orlistat on bodyweight, glycemic control and cardiovascular risk factors in overweight or obese South African patients with type 2 diabetes [abstract], Diabetes, 51, A412
- Derrochanawong C, 2001, Effect of treatment with orlistat in overweight or obese Thai patients with type 2 diabetes [abstract], Diabetes, 50
Cited by
Obesity and cardiovascular disease: An ESC clinical consensus statement
Koskinas, K. C., Van Craenenbroeck, E. M., Antoniades, C., Blüher, M., Gorter, T. M., Hanssen, H., Marx, N., McDonagh, T. A., Mingrone, G., Rosengren, A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae508 · Cited by 313
Evolution of NAFLD and Its Management
Mundi, M. S., Velapati, S., Patel, J., Kellogg, T. A., Abu Dayyeh, B. K., & Hurt, R. T. (2020) · Nutrition in Clinical Practice · doi:10.1002/ncp.10449 · Cited by 285
Mathus-Vliegen, E. M. H., Basdevant, A., Finer, N., Hainer, V., Hauner, H., Micic, D., Maislos, M., Roman, G., Schutz, Y., Tsigos, C., et al. (2012) · Obesity Facts · doi:10.1159/000341193 · Cited by 261
Zomer, E., Gurusamy, K., Leach, R., Trimmer, C., Lobstein, T., Morris, S., James, W. P. T., & Finer, N. (2016) · Obesity Reviews · doi:10.1111/obr.12433 · Cited by 236
“As expected, the studies using orlistat found more adverse gastrointestinal side effects; on the other hand, it is thought that orlistat may have specific actions in reducing LDL cholesterol and improving insulin sensitivity (31,32).”
ResultWeight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment
Van Gaal, L., & Scheen, A. (2015) · Diabetes Care · doi:10.2337/dc14-1630 · Cited by 221
Metadata
- Authors
- Jacob, S., Rabbia, M., Meier, M. K., & Hauptman, J.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2009-02-24
- Volume
- 11
- Issue
- 4
- Pages
- 361-371
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W1988187729
- Cited by
- 72
- References
- 17
- FWCI
- 2.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss. https://app.cochat.ai/papers/10.1111/j.1463-1326.2008.00970.x
- The paper
- Jacob, S., Rabbia, M., Meier, M. K., & Hauptman, J. (2009). Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2008.00970.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.